1. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
- Author
-
Tunn UW and Wiedey K
- Subjects
- Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Delayed-Action Preparations, Europe, Follicle Stimulating Hormone blood, Humans, Leuprolide adverse effects, Leuprolide blood, Luteinizing Hormone blood, Luteinizing Hormone drug effects, Male, Prostate-Specific Antigen blood, Prostate-Specific Antigen drug effects, Prostatic Neoplasms blood, Testosterone blood, Antineoplastic Agents administration & dosage, Leuprolide administration & dosage, Prostatic Neoplasms drug therapy
- Abstract
This multicentre European study compared the safety and tolerability of the existing 11.25 mg 3-month depot of leuprorelin acetate with a new 30 mg 6-month depot in men with newly diagnosed prostate cancer or prostate-specific antigen relapse after radiotherapy or prostatectomy. The primary end points were safety and tolerability and secondary end points were clinical response based on European Organization for Research and Treatment of Cancer (EORTC) criteria and response rate by time point for testosterone suppression (castrate level
- Published
- 2009
- Full Text
- View/download PDF